SEC Form 6-K filed by Kazia Therapeutics Limited

3/19/26 5:09:25 PM ET

$KZIA

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $KZIA alert in real time by email

6-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form

6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE

13a-16

15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of

March

, 2026

Commission File Number

000-29962

Kazia Therapeutics Limited

(Translation of registrant’s name into English)

Three International Towers Level 24 300 Barangaroo Avenue Sydney NSW 2000

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form

20-F

or Form

40-F.

Form

20-F ☒ Form

40-F ☐

INFORMATION CONTAINED IN THIS FORM

6-K

REPORT

On March 16, 2026 AEDT, Kazia Therapeutics Limited (the “Company”) reported its unaudited half-year results for the six months ended December 31, 2025, a copy of which is attached to this Form

6-K

as Exhibit 99.1.

The Company hereby incorporates by reference the information contained herein, including Exhibit 99.1, into the Company’s

registration

statements on Form

F-3

(File

No. 333-281937).

EXHIBIT LIST


Exhibit		Description

99.1		Half-year report for the six months ended December 31, 2025

101.INS		XBRL Instance Document

101.SCH		XBRL Taxonomy Extension Schema Document

101.CAL		XBRL Taxonomy Extension Calculation Linkbase Document

101.DEF		XBRL Taxonomy Extension Definition Linkbase Document

101.LAB		XBRL Taxonomy Extension Label Linkbase Document

101.PRE		XBRL Taxonomy Extension Presentation Linkbase Document

104		Cover Page Interactive Data File (embedded within the Inline XBRL document )

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Kazia Therapeutics Limited

(Registrant)

/s/ John Friend

Name: John Friend

Title: Chief Executive Officer

Date: March 19,

2026

Get the next $KZIA alert in real time by email

Date

Price Target

Rating

Analyst

2/6/2025

$3.00

Buy

Maxim Group

10/14/2021

$18.00

Buy

Maxim Group

SEC Form 6-K filed by Kazia Therapeutics Limited

3/19/26 5:09:25 PM ET

$KZIA

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $KZIA alert in real time by email

6-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form

6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE

13a-16

15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of

March

, 2026

Commission File Number

000-29962

Kazia Therapeutics Limited

(Translation of registrant’s name into English)

Three International Towers Level 24 300 Barangaroo Avenue Sydney NSW 2000

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form

20-F

or Form

40-F.

Form

20-F ☒ Form

40-F ☐

INFORMATION CONTAINED IN THIS FORM

6-K

REPORT

On March 16, 2026 AEDT, Kazia Therapeutics Limited (the “Company”) reported its unaudited half-year results for the six months ended December 31, 2025, a copy of which is attached to this Form

6-K

as Exhibit 99.1.

The Company hereby incorporates by reference the information contained herein, including Exhibit 99.1, into the Company’s

registration

statements on Form

F-3

(File

No. 333-281937).

EXHIBIT LIST


Exhibit		Description

99.1		Half-year report for the six months ended December 31, 2025

101.INS		XBRL Instance Document

101.SCH		XBRL Taxonomy Extension Schema Document

101.CAL		XBRL Taxonomy Extension Calculation Linkbase Document

101.DEF		XBRL Taxonomy Extension Definition Linkbase Document

101.LAB		XBRL Taxonomy Extension Label Linkbase Document

101.PRE		XBRL Taxonomy Extension Presentation Linkbase Document

104		Cover Page Interactive Data File (embedded within the Inline XBRL document )

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Kazia Therapeutics Limited

(Registrant)

/s/ John Friend

Name: John Friend

Title: Chief Executive Officer

Date: March 19,

2026

Get the next $KZIA alert in real time by email

Date

Price Target

Rating

Analyst

2/6/2025

$3.00

Buy

Maxim Group

10/14/2021

$18.00

Buy

Maxim Group

SEC Form 6-K filed by Kazia Therapeutics Limited

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for
$KZIA

SEC Form 6-K filed by Kazia Therapeutics Limited

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for
$KZIA

$KZIA
SEC Filings

SEC Form 424B3 filed by Kazia Therapeutics Limited

SEC Form 424B3 filed by Kazia Therapeutics Limited

SEC Form 424B3 filed by Kazia Therapeutics Limited

$KZIA
Press Releases

Kazia Therapeutics Announces Compelling Preclinical and Translational Data for Nuclear PD-L1 Degrader (NDL2)

Kazia Therapeutics Reports Encouraging Preliminary Clinical Responses in Ongoing Phase 1b Study of Paxalisib in Late-Stage Metastatic Triple-Negative Breast Cancer

Kazia Therapeutics to Participate in J.P. Morgan Healthcare Conference Week; Clinical and Translational Update Anticipated Before Month-End

$KZIA
Analyst Ratings

Maxim Group initiated coverage on Kazia Therapeutics with a new price target

Maxim Group initiated coverage on Kazia Therapeutics with a new price target

$KZIA
Insider Trading

SEC Form 3 filed by new insider Coffey Steven R. S.

SEC Form 3 filed by new insider Friend John E. Ii

SEC Form 3 filed by new insider Simpson Jeremy

$KZIA
Large Ownership Changes

Amendment: SEC Form SC 13G/A filed by Kazia Therapeutics Limited

SEC Form SC 13G filed by Kazia Therapeutics Limited

Amendment: SEC Form SC 13G/A filed by Kazia Therapeutics Limited

$KZIA
Leadership Updates

KAZIA CONTINUES BOARD RENEWAL WITH TWO NEW APPOINTMENTS

KAZIA THERAPEUTICS APPOINTS KAREN KRUMEICH AS CHIEF FINANCIAL OFFICER

Kazia Therapeutics Appoints John Friend, MD, as Chief Medical Officer

SEC Form 6-K filed by Kazia Therapeutics Limited

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for $KZIA

SEC Form 6-K filed by Kazia Therapeutics Limited

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for $KZIA

$KZIA SEC Filings

SEC Form 424B3 filed by Kazia Therapeutics Limited

SEC Form 424B3 filed by Kazia Therapeutics Limited

SEC Form 424B3 filed by Kazia Therapeutics Limited

$KZIA Press Releases

Kazia Therapeutics Announces Compelling Preclinical and Translational Data for Nuclear PD-L1 Degrader (NDL2)

Kazia Therapeutics Reports Encouraging Preliminary Clinical Responses in Ongoing Phase 1b Study of Paxalisib in Late-Stage Metastatic Triple-Negative Breast Cancer

Kazia Therapeutics to Participate in J.P. Morgan Healthcare Conference Week; Clinical and Translational Update Anticipated Before Month-End

$KZIA Analyst Ratings

Maxim Group initiated coverage on Kazia Therapeutics with a new price target

Maxim Group initiated coverage on Kazia Therapeutics with a new price target

$KZIA Insider Trading

SEC Form 3 filed by new insider Coffey Steven R. S.

SEC Form 3 filed by new insider Friend John E. Ii

SEC Form 3 filed by new insider Simpson Jeremy

$KZIA Large Ownership Changes

Amendment: SEC Form SC 13G/A filed by Kazia Therapeutics Limited

SEC Form SC 13G filed by Kazia Therapeutics Limited

Amendment: SEC Form SC 13G/A filed by Kazia Therapeutics Limited

$KZIA Leadership Updates

KAZIA CONTINUES BOARD RENEWAL WITH TWO NEW APPOINTMENTS

KAZIA THERAPEUTICS APPOINTS KAREN KRUMEICH AS CHIEF FINANCIAL OFFICER

Kazia Therapeutics Appoints John Friend, MD, as Chief Medical Officer

Recent Analyst Ratings for
$KZIA

Recent Analyst Ratings for
$KZIA

$KZIA
SEC Filings

$KZIA
Press Releases

$KZIA
Analyst Ratings

$KZIA
Insider Trading

$KZIA
Large Ownership Changes

$KZIA
Leadership Updates